Emerald Health Pharmaceuticals, a division of Emerald Health Therapeutics (TSXV:EMH), announced key members of its scientific team found the potential for EHP-102, a patented aminoquinone derivative of the non-psychoactive phytocannabinoid, to treat Parkinson’s disease.
As quoted in the press release:
This research was done in collaboration with Professor Javier Fernandez-Ruiz (University Complutense of Madrid, Spain).
These results were published in the Journal of Neuroinflammation in a scientific paper entitled, “Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation driven neuronal deterioration in experimental Parkinson’s disease: possible involvement of different binding sites at the PPARγ receptor.” Co-authors of this paper included Eduardo Muñoz, MD, PhD, EHP’s Chief Scientific Officer and Mari-Luz Bellido, PhD, EHP’s Vice President of European Operations.
Researchers evaluated the anti-inflammatory and neuroprotective properties of EHP-102 in two animal models of Parkinson’s disease, as well as in vitro cellular models. Findings showed that EHP-102 is neuroprotective against inflammation-driven neuronal damage in these models. EHP-102 is a peroxisome proliferator-activated receptor-γ (PPARγ) modulator acting on both the canonical and alternative binding sites. These data demonstrate that EHP-102 could potentially be used as a neuroprotective agent in Parkinson’s disease due to its multi-target properties specific to the disease.